MX2011013558A - Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. - Google Patents
Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos.Info
- Publication number
- MX2011013558A MX2011013558A MX2011013558A MX2011013558A MX2011013558A MX 2011013558 A MX2011013558 A MX 2011013558A MX 2011013558 A MX2011013558 A MX 2011013558A MX 2011013558 A MX2011013558 A MX 2011013558A MX 2011013558 A MX2011013558 A MX 2011013558A
- Authority
- MX
- Mexico
- Prior art keywords
- tocotrienol
- developmental disorders
- disorder
- pervasive developmental
- tocotrienols
- Prior art date
Links
- 229930003802 tocotrienol Natural products 0.000 title abstract 6
- 239000011731 tocotrienol Substances 0.000 title abstract 6
- 235000019148 tocotrienols Nutrition 0.000 title abstract 6
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 title abstract 4
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 4
- 208000012202 Pervasive developmental disease Diseases 0.000 title abstract 3
- 239000000284 extract Substances 0.000 title abstract 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 title 1
- 229940068778 tocotrienols Drugs 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 208000024825 childhood disintegrative disease Diseases 0.000 abstract 2
- 208000036640 Asperger disease Diseases 0.000 abstract 1
- 201000006062 Asperger syndrome Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000036353 Rett disease Diseases 0.000 abstract 1
- 201000007197 atypical autism Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 tocotrienol ester Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26962709P | 2009-06-25 | 2009-06-25 | |
| PCT/US2010/025447 WO2010151348A1 (en) | 2009-06-25 | 2010-02-25 | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011013558A true MX2011013558A (es) | 2012-04-30 |
Family
ID=43386829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013558A MX2011013558A (es) | 2009-06-25 | 2010-02-25 | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120122969A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2445519A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012531411A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1011776A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2765771A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201200054A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011013558A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010151348A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| JP6460998B2 (ja) * | 2012-11-13 | 2019-01-30 | インビクタス バイオテクノロジー プロプライエタリー リミテッド | トコトリエノールの経粘膜送達 |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2015013285A2 (en) * | 2013-07-22 | 2015-01-29 | Ohio State Innovation Foundation | Methods for reducing the occurrence of hot flashes |
| NZ733528A (en) | 2014-12-16 | 2021-07-30 | Ptc Therapeutics Inc | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US20220214358A1 (en) * | 2019-04-05 | 2022-07-07 | Arizona Board Of Regents On Behalf Of Arizona State University | Diagnostic for childhood risk of autism spectrum disorder |
| MY196888A (en) * | 2019-11-19 | 2023-05-08 | Hovid Berhad | A composition for managing cadasil |
| EP3981397A1 (en) * | 2020-10-08 | 2022-04-13 | Global Scientific | Tocotrienols derivates, methods and uses thereof |
| CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| JPH029875A (ja) | 1988-03-16 | 1990-01-12 | Bio Ind Kyokai | トコフェロール及びトコトリエノールの製造方法 |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| EP0543417A1 (en) | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US20030134028A1 (en) * | 1995-06-01 | 2003-07-17 | Lipton, Division Of Conopco, Inc. | Fat based food products |
| JP2002501915A (ja) | 1998-01-29 | 2002-01-22 | イーストマン ケミカル カンパニー | トコール含有混合物からのトコールの分離方法 |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6187811B1 (en) * | 1998-10-28 | 2001-02-13 | Lipogenics, Inc. | Methods for treating benign prostatic hyperplasia using tocotrienols |
| WO2000027393A1 (en) | 1998-11-06 | 2000-05-18 | Fuji Chemical Industry Co., Ltd. | Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US7217133B2 (en) * | 2002-04-04 | 2007-05-15 | Jeanine Thomas | Method for treating pervasive development disorder |
| AT414082B (de) * | 2002-05-03 | 2006-09-15 | Vis Vitalis Lizenz & Handels | Verfahren zur herstellung von tocotrienol-angereicherten präparationen |
| WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
| MXPA06009529A (es) | 2004-02-23 | 2007-04-10 | Texas A & M Univ Sys | Composiciones antioxidantes y metodos para el uso de las mismas. |
| US10300034B2 (en) * | 2007-02-22 | 2019-05-28 | Children's Hospital Of Oakland Research Institute | Fatty acid formulations and methods of use thereof |
| KR101481197B1 (ko) | 2007-05-24 | 2015-01-09 | 로더스 크로클란 비.브이. | 토코페롤 및 토코트리에놀을 함유하는 조성물의 제조방법 |
-
2010
- 2010-02-25 US US13/380,802 patent/US20120122969A1/en not_active Abandoned
- 2010-02-25 WO PCT/US2010/025447 patent/WO2010151348A1/en not_active Ceased
- 2010-02-25 JP JP2012517509A patent/JP2012531411A/ja active Pending
- 2010-02-25 CA CA2765771A patent/CA2765771A1/en not_active Abandoned
- 2010-02-25 MX MX2011013558A patent/MX2011013558A/es not_active Application Discontinuation
- 2010-02-25 EA EA201200054A patent/EA201200054A1/ru unknown
- 2010-02-25 EP EP10792467A patent/EP2445519A4/en not_active Withdrawn
- 2010-02-25 BR BRPI1011776A patent/BRPI1011776A2/pt not_active IP Right Cessation
- 2010-02-25 EP EP13161401.8A patent/EP2609921A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EA201200054A1 (ru) | 2012-05-30 |
| CA2765771A1 (en) | 2010-12-29 |
| EP2445519A4 (en) | 2012-12-26 |
| WO2010151348A1 (en) | 2010-12-29 |
| EP2609921A1 (en) | 2013-07-03 |
| JP2012531411A (ja) | 2012-12-10 |
| EP2445519A1 (en) | 2012-05-02 |
| BRPI1011776A2 (pt) | 2018-03-13 |
| US20120122969A1 (en) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013558A (es) | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. | |
| MX360598B (es) | Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos. | |
| CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| WO2012174487A8 (en) | Bromodomain inhibitors and uses thereof | |
| WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
| MX363223B (es) | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. | |
| IN2012DN02645A (cg-RX-API-DMAC7.html) | ||
| MX2009004798A (es) | Tratamiento de los trastornos generalizados del desarrollo. | |
| TN2016000238A1 (en) | Tricyclic compounds as anticancer agents. | |
| MX2016001037A (es) | Inhibidores de factores de transcripción y usos. | |
| IN2015KN00414A (cg-RX-API-DMAC7.html) | ||
| PH12016500040A1 (en) | Pcsk9 vaccine | |
| NZ700928A (en) | Dna-pk inhibitors | |
| NZ706739A (en) | Substituted benzene compounds | |
| MX365205B (es) | Preparaciones liofilizadas de melfalán flufenamida. | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| IN2014MN02269A (cg-RX-API-DMAC7.html) | ||
| MY158200A (en) | Conjugates for the prevention of treatment of nicotine addiction | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| IN2012DN00239A (cg-RX-API-DMAC7.html) | ||
| MX374590B (es) | Composición para usarse en el tratamiento de la tos. | |
| IN2014MN01933A (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |